SAN FRANCISCO, CA / April 22, 2019 / According to The American Cancer Society (ACS) breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average risk of a woman in the United States developing breast cancer sometime in her life is about 12%. This means there is a 1 in 8 chance she will develop breast cancer. This also means there is a 7 in 8 chance she will never have the disease. The American Cancer Society estimates there will be about 268,600 new cases of invasive breast cancer diagnosed in women in the United States for 2019.
A new study performed by a team at Harvard Medical School has unexpectedly found that amino acid, leucine, may play a role in the formation of resistance to a certain drug, tamoxifen, that it used to treat estrogen receptor-positive (ER-positive) breast cancer.
Dr. Steven Quay, CEO of Atossa Genetics (NASDAQ: ATOS) stated, "having studied leucine metabolism for my Ph.D. in biological chemistry at the beginning of my career, this finding makes total sense. Cancer is a disease characterized by both genetic changes, that provide the "motivation" to grow abnormally, and metabolic changes, that provide the "means" to grow abnormally. Leucine sits at the hub of metabolic pathways that have broad, pleomorphic effects. This paper joins scores of others that show the powerful effects of metabolism, including diet, on cancer growth. In our research here at Atossa Genetics, we are always watching for signs of the interplay of genetics and metabolism to help inform our clinical stage, development programs for the prevention and treatment of breast cancer."
Read Complete Story.
About Vista Partners LLC:
Founded in 2005, Vista Partners LLC ("Vista") is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista's proprietary equity and market research to help you stay informed and stay competitive. Vista's mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. Stay Informed! Stay Competitive! Receive FREE email updates.
We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.